Kenvue Inc.
Rank #198ValueKVUE · NYSE · Consumer Defensive
Kenvue Inc. (KVUE) — Rank #198 by gross profitability (GP/assets 0.33) · ROE 13.9% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001944048 · all metrics point-in-time as of the filing date.
About
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
Show moreShow less
It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc.
was incorporated in 2022 and is headquartered in Summit, New Jersey.
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- January 3
- Website
- kenvue.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-28filed 2026-02-20 | 2024-12-29filed 2025-02-24 | 2023-12-31filed 2024-03-01 | 2023-01-01filed 2024-03-01 |
|---|---|---|---|---|
| Assets | ||||
| Cash & equivalents | 1,062.0 | 1,070.0 | 1,382.0 | 1,231.0 |
| Accounts receivable | 2,382.0 | 2,165.0 | 2,073.0 | 2,122.0 |
| Inventory | 1,666.0 | 1,591.0 | 1,851.0 | 2,226.0 |
| Total current assets | 5,697.0 | 5,525.0 | 6,138.0 | 5,877.0 |
| Property, plant & equipment, net | 2,212.0 | 1,849.0 | 2,042.0 | 1,820.0 |
| Goodwill | 9,509.0 | 8,843.0 | 9,271.0 | 9,185.0 |
| Intangible assets (excl. goodwill) | 8,694.0 | 8,474.0 | 9,619.0 | 9,853.0 |
| Total assets | 27,076.0 | 25,601.0 | 27,851.0 | 27,316.0 |
| Liabilities | ||||
| Accounts payable | 2,473.0 | 2,254.0 | 2,489.0 | 1,829.0 |
| Accrued liabilities | 1,159.0 | 1,132.0 | 1,456.0 | 906.0 |
| Total current liabilities | 5,945.0 | 5,739.0 | 5,481.0 | 3,926.0 |
| Total debt | 1,453.0 | 1,552.0 | 8,286.0 | 0.0 |
| Total liabilities | 16,311.0 | 15,933.0 | 16,640.0 | 7,346.0 |
| Equity | ||||
| Retained earnings | (204.0) | (93.0) | 429.0 | 0.0 |
| Total shareholders' equity | 10,765.0 | 9,668.0 | 11,211.0 | 19,970.0 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?